secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001558370-22-000026
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics expands credit facility to $200M, extends maturity to 2026
--------------------------------------------------------------------------

- Loan increased from $60M to $200M; initial $70M drawn, $7.8M used to refinance existing balance.
- Maturity extended to Jan 1, 2026; interest-only period extended to Feb 1, 2025 (extendable to Aug 1, 2025).
- Interest rate: prime + 2.15% (floor 5.40%); warrants issued for 115,042 shares at $17.95, 7-year term.
- Financial covenants: minimum cash from Oct 15, 2022; market cap/cash covenants from July 1, 2023 if drawn >$70M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/0001558370-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/tgtx-20211230x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer